Q-omics provides the consensus-scored MS4A4E profile across patient tissues and cancer cell-line models. MS4A4E expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MS4A4E is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MS4A4E RNA expression shows 23,516 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where MS4A4E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MS4A4E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MS4A4E survival associations across molecular data types. MS4A4E RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MS4A4E RNA expression–survival associations across cancer types. High MS4A4E expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, PAAD, SKCM and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for MS4A4E RNA expression.
This table summarizes MS4A4E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MS4A4E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MS4A4E shows lower tumor expression in COAD, LUSC, BRCA and UCEC and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher MS4A4E RNA expression in tumor versus normal tissue (log2 FC = +0.847, t-test p < 0.001).
This table shows molecular features associated with MS4A4E in patient tissues and cancer cell lines. In patient samples, MS4A4E shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MS4A4E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
